Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene Starts Clinical Trial of Novel Lymphoma/Solid Tumor Cancer Treatment

publication date: Apr 14, 2020

Antengene, a Shanghai-US biopharma, has dosed the first patient in a Taiwan Phase I trial of ATG-019, a dual inhibitor of PAK4 and NAMPT. The trial will enroll patients with advanced solid tumors or non-Hodgkin's lymphoma. Antengene says ATG-019 is a first-in-class, oral inhibitor targeting p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyl transferase (NAMPT). In 2018, Antengene in-licensed China rights to ATG-019 and three other novel oral cancer treatments from Karyopharm (NSDQ: KPTI) of Boston in an $162 million agreement. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital